<DOC>
	<DOC>NCT01463891</DOC>
	<brief_summary>To investigate of the clinical safety and effectiveness of eribulin mesylate in patients with inoperable or recurrent breast cancer</brief_summary>
	<brief_title>Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion criteria : Inoperable breast cancer Recurrent breast cancer Exclusion criteria : Corresponding to contraindication of eribulin mesylate Not applicable to indications of eribulin mesylate Not applicable to aggravation or recurrence of breast cancer in patients who have previously been treated with anthracycline and/or taxane antitumor drugs</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Eribulin Mesylate</keyword>
	<keyword>inoperable or recurrent breast cancer</keyword>
</DOC>